Study of PLZF/RARA Target Genes in Acute Promyelocytic Leukemia
Author Information
Author(s): Spicuglia Salvatore, Vincent-Fabert Christelle, Benoukraf Touati, Tibéri Guillaume, Saurin Andrew J., Zacarias-Cabeza Joaquin, Grimwade David, Mills Ken, Calmels Boris, Bertucci François, Sieweke Michael, Ferrier Pierre, Duprez Estelle
Primary Institution: Centre d'Immunologie de Marseille-Luminy (CIML), Université de la Méditerranée, Marseille, France
Hypothesis
The PLZF/RARA fusion protein acts as an oncogenic transcriptional regulator in acute promyelocytic leukemia (APL).
Conclusion
The study identifies 413 specific PLZF/RARA target genes that are important for hematopoietic development and are significantly downregulated in primary PLZF/RARA APL cells.
Supporting Evidence
- 413 specific PLZF/RARA target genes were identified.
- 22 of these genes were significantly downregulated in primary PLZF/RARA APL cells.
- PLZF/RARA binding was associated with increased H3K27me3 and decreased H3K9K14ac levels.
Takeaway
This study found that a protein involved in a type of leukemia can turn off important genes that help blood cells develop properly.
Methodology
The study used ChIP-on-chip analysis to identify PLZF/RARA target genes in a cell line expressing the fusion protein.
Limitations
The study primarily focuses on a specific cell line and may not fully represent the complexity of APL in patients.
Statistical Information
P-Value
4.99×10−9
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website